Taylor Patricia L, Wright Gerard D
Michael G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, 1200 Main St. W., Hamilton, ON L8N3Z5, Canada.
Anim Health Res Rev. 2008 Dec;9(2):237-46. doi: 10.1017/S1466252308001527. Epub 2008 Nov 13.
Antimicrobial resistance is a rapidly increasing problem impacting the successful treatment of bacterial infectious disease. To combat resistance, the development of new treatment options is required. Recent advances in technology have aided in the discovery of novel antibacterial agents, specifically through genome mining for novel natural product biosynthetic gene clusters and improved small molecule high-throughput screening methods. Novel targets such as lipopolysaccharide and fatty acid biosyntheses have been identified by essential gene studies, representing a shift from traditional antibiotic targets. Finally, inhibiting non-essential genes with small molecules is being explored as a method for rescuing the activity of 'old' antibiotics, providing a novel synergistic approach to antimicrobial discovery.
抗菌药物耐药性是一个迅速加剧的问题,影响着细菌感染性疾病的成功治疗。为了对抗耐药性,需要开发新的治疗方案。技术上的最新进展有助于发现新型抗菌剂,特别是通过对新型天然产物生物合成基因簇进行基因组挖掘以及改进小分子高通量筛选方法。通过必需基因研究已确定了诸如脂多糖和脂肪酸生物合成等新型靶点,这代表着与传统抗生素靶点的转变。最后,正在探索用小分子抑制非必需基因作为挽救“老”抗生素活性的一种方法,为抗菌药物发现提供了一种新型协同方法。